Boxer Capital’s Avidity Biosciences RNAM Stock Holding History

Boxer Capital’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,727,388	Closed	-$79.3M	–	46
2024 Q3	$79.3M	Hold	1,727,388	–	–	3.89%	9
2024 Q2	$70.6M	Hold	1,727,388	–	–	3.72%	10
2024 Q1	$44.1M	Buy	1,727,388 +606,061	+54%	+$9.5M	2.18%	14
2023 Q4	$10.1M	Hold	1,121,327	–	–	0.51%	34
2023 Q3	$7.15M	Hold	1,121,327	–	–	0.38%	48
2023 Q2	$12.4M	Hold	1,121,327	–	–	0.58%	44
2023 Q1	$17.2M	Hold	1,121,327	–	–	0.85%	36
2022 Q4	$24.9M	Hold	1,121,327	–	–	1.31%	29
2022 Q3	$18.3M	Hold	1,121,327	–	–	1.03%	35
2022 Q2	$16.3M	Hold	1,121,327	–	–	1.03%	34
2022 Q1	$20.7M	Hold	1,121,327	–	–	1.06%	30
2021 Q4	$26.7M	Hold	1,121,327	–	–	1.04%	26
2021 Q3	$27.6M	Hold	1,121,327	–	–	0.96%	29
2021 Q2	$27.7M	Hold	1,121,327	–	–	0.98%	27
2021 Q1	$24.5M	Hold	1,121,327	–	–	0.83%	35
2020 Q4	$28.6M	Hold	1,121,327	–	–	0.92%	31
2020 Q3	$31.6M	Hold	1,121,327	–	–	1.09%	25
2020 Q2	$31.7M	Buy	+1,121,327	New	+$32.3M	1.39%	25

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital's RNAM Position: Q4 2024 in Review

Boxer Capital sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 1,727,388 shares — an estimated $79.3M sold.

Boxer Capital first reported a position in RNAM in Q2 2020 and held it in 18 quarters. The position peaked at $79.3M in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

Boxer Capital reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 1,727,388 Avidity Biosciences shares in Q4 2024, an estimated $79.3M.
Boxer Capital first reported a position in Avidity Biosciences in Q2 2020 and held it in 18 quarters.
Boxer Capital's Avidity Biosciences position peaked at $79.3M in Q3 2024.
236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.